A scientific thesis on longevity medicine — how blood, DNA, and continuous biomarker intelligence can reverse biological age, prevent metabolic disease, and redefine what optimal human health looks like in India and beyond.
Medicine has operated for a century on a reactive model: wait for disease to present, then treat it. This model has been extraordinarily successful at extending lifespan — but it has almost entirely failed to extend healthspan, the period of biological life free from chronic disease, cognitive decline, and functional deterioration.
The average Indian professional today will spend the last 10–15 years of their life managing the compounding consequences of decades of metabolic dysfunction that was both detectable and addressable years earlier.
"Ageing is not the ticking of a clock. It is the accumulation of addressable biological errors — in epigenetic programming, metabolic signalling, cellular senescence, and mitochondrial efficiency — each of which is now measurable, and increasingly reversible."
The longevity hypothesis, as synthesised from the work of Dr. David Sinclair (Harvard Medical School), Dr. Peter Attia (Early Medical), and Bryan Johnson (Blueprint), holds three core propositions:
1. Biological age and chronological age are different things. Epigenetic clocks — algorithms trained on DNA methylation patterns — can now measure biological age to within 2 years. Two 45-year-olds with the same birthdate can have biological ages of 38 and 56 respectively, depending on their lifestyle, metabolic state, and epigenetic history. This difference is not genetic fate. It is addressable biology.
2. The trajectory of ageing is more important than the current measurement. DunedinPACE — developed at Duke University — measures not biological age but the pace at which biological age is accumulating. A DunedinPACE of 0.78 means you are ageing at 78% of the normal rate. This metric moves with intervention. It is the vital sign that 20th-century medicine forgot to invent.
3. The interventions that slow biological ageing also prevent the diseases of ageing. Cardiovascular disease, type 2 diabetes, Alzheimer's, cancer, and sarcopenia are not independent conditions requiring separate treatments. They are downstream expressions of the same upstream biological dysfunction — metabolic dysregulation, chronic inflammation, mitochondrial impairment, and epigenetic drift. Address the upstream biology and the downstream diseases move.
The longevity crisis is global. But India has a specific, distinct, and underaddressed biological profile that makes generic Western longevity protocols insufficient. The data is unambiguous.
Source: ICMR-INDIAB-17, The Lancet Diabetes & Endocrinology, 2023 — the largest nationally representative metabolic health study ever conducted in India (113,043 participants across 31 states)
South Asians develop metabolic disease at body weights and BMI levels where Western medicine considers them healthy. The WHO Asia Pacific guidelines use different obesity thresholds for South Asians — 23 kg/m² for overweight, 27.5 for obesity — because the metabolic damage begins earlier at lower adiposity in Indian bodies.
Three mechanisms drive this:
Insulin resistance at lower BMI. South Asians have higher visceral adipose tissue and lower subcutaneous fat at equivalent BMIs to Europeans. Visceral fat is metabolically active — it secretes inflammatory cytokines, impairs insulin signalling, and elevates FFA (free fatty acids) that drive hepatic de novo lipogenesis directly. This is why HOMA-IR thresholds validated in European populations systematically underestimate metabolic risk in Indians.
The Indian lipid paradox. The atherogenic dyslipidaemia pattern in Indians is characteristically high TG, low HDL, and elevated small-dense LDL — despite sometimes-normal total cholesterol. Standard total cholesterol or LDL measurements miss this pattern. ApoB — the particle count, not the cholesterol content — is the accurate risk marker. A 40-year-old Indian professional with LDL 140 and ApoB 130 has a cardiovascular risk profile that looks normal on a standard panel and alarming on a proper one.
Dietary transition to high-glycaemic carbohydrates. The ICMR-INDIAB dietary analysis found that Indians eating the highest quantities of low-quality carbohydrates — white rice, milled whole grains, added sugar — had a 30% higher risk of newly diagnosed type 2 diabetes and 22% higher abdominal obesity compared to those eating the least. The Indian diet, historically diverse and metabolically protective in its traditional form, has undergone a 30-year shift toward refined carbohydrate dominance — with measurable consequences in population-level data.
"We built a metabolic crisis on rice, roti, and the dietary mythology of the last 40 years. Every longevity protocol applied to an Indian body must be calibrated to Indian biology — not translated from a European clinical trial."
Dr. David Sinclair's Information Theory of Ageing, published in Cell and developed over two decades of work at Harvard Medical School, proposes that ageing is fundamentally a loss of epigenetic information — not genetic damage.
The distinction is critical. Your genome — the sequence of 3 billion base pairs in every cell — remains largely intact throughout your lifetime. What changes is the epigenome: the pattern of chemical modifications that determine which genes are expressed, when, and in which tissues. This epigenetic programme encodes the youthful identity of every cell type. As it degrades, cells lose their functional identity, adopt dysfunctional gene expression profiles, and produce the phenotypic changes we call ageing.
In 2013, Steve Horvath at UCLA identified that specific DNA methylation sites — where methyl groups attach to cytosine bases — change in predictable, age-correlated patterns across virtually all human tissue types. The Horvath Clock, and subsequent refinements including Hannum, PhenoAge, GrimAge, and the most recent DunedinPACE, convert these methylation patterns into biological age estimates and ageing pace measurements with validated clinical predictive power.
TruAge and GrimAge predict biological age — where you are on the biological ageing curve relative to your chronological peers. Studies show GrimAge outperforms chronological age in predicting all-cause mortality, cardiovascular disease incidence, and cancer risk.
DunedinPACE measures the rate of change — how fast biological age is accumulating per year of chronological time. Published in eLife in 2022, DunedinPACE was validated against 45 biomarkers of organ system ageing in a 38-year longitudinal cohort study. A DunedinPACE of 1.0 is population average. Values above 1.0 indicate accelerated ageing. Crucially, DunedinPACE responds to intervention within 12–24 weeks — making it an actionable clinical tool, not just an epidemiological curiosity.
Sirtuins (SIRT1–SIRT7) are the primary enzymes responsible for maintaining epigenetic information fidelity. They require NAD⁺ as a cofactor — and NAD⁺ declines approximately 50% between ages 40 and 60 in most human tissues. As NAD⁺ falls, sirtuin activity falls, epigenetic maintenance degrades, and biological ageing accelerates.
This is the mechanistic rationale for NAD⁺ precursor supplementation (NMN, NR) and for interventions that activate AMPK — the cellular energy sensor that upregulates sirtuin activity. Caloric restriction, time-restricted eating, exercise, metformin, and berberine all activate AMPK through partially overlapping pathways. The longevity effects of these interventions are not separate — they converge on the same upstream biology.
| Gene/Pathway | Function | Activated by | Clinical relevance |
|---|---|---|---|
| SIRT1 | Epigenetic maintenance, DNA repair | NAD⁺, caloric restriction, resveratrol | Central regulator of metabolic ageing |
| SIRT3 | Mitochondrial efficiency, ROS management | NAD⁺, exercise, fasting | Muscle and cardiac function preservation |
| AMPK | Cellular energy sensing, mTOR inhibition | Berberine, metformin, fasting, exercise | Insulin sensitivity, autophagy activation |
| mTOR | Protein synthesis, cell growth | Amino acids, insulin | Inhibition → longevity; overactivation → cancer risk |
| FOXO3 | DNA repair, stress resistance | Fasting, AMPK activation | Strongly associated with human centenarian status |
| IGF-1/GH axis | Growth, anabolism, body composition | Sleep, peptides (CJC-1295) | Decline drives sarcopenia and metabolic disease |
Dr. Peter Attia's framework for longevity medicine — developed across a decade of clinical practice and synthesised in his New York Times bestseller Outlive — identifies five domains that determine both lifespan and healthspan. Each domain has precise, measurable biomarkers. Each responds to specific, evidence-based interventions. Each is tracked in the 150 programme.
VO2 Max is the single strongest predictor of all-cause mortality available. Moving from the bottom to the top quartile of VO2 Max for age confers a 5× reduction in mortality risk — greater than the benefit of quitting smoking. Zone 2 aerobic training (60–70% max HR) drives mitochondrial biogenesis, AMPK activation, and fat oxidation capacity. Strength training preserves lean mass and bone density — the tissues that determine functional independence in the last decade of life.
Time-restricted eating and protein adequacy are the two highest-leverage nutritional interventions. Fasting activates autophagy, AMPK, and sirtuins — mimicking the longevity signal of caloric restriction without the impracticality. Protein at 1.6–2.2g/kg/day preserves lean mass and supports liver detoxification. For Indians specifically: the shift from high-glycaemic carbohydrate dominance to fibre-first, protein-adequate meals is the single most impactful dietary intervention available without a prescription.
Sleep quality governs growth hormone pulsatility (90% of daily GH secretion occurs during deep sleep), cortisol diurnal rhythm, HRV recovery, and glymphatic brain clearance. HRV — the 7-day average from wearable monitoring — is the most sensitive daily indicator of autonomic recovery and biological resilience. In the 150 protocol, HRV tracks the response to every intervention before blood markers move.
Chronic psychological stress dysregulates the HPA (hypothalamic-pituitary-adrenal) axis, producing a blunted morning cortisol peak and elevated evening cortisol — the "tired and wired" pattern. This pattern reduces LDL receptor expression (contributing to dyslipidaemia), suppresses testosterone synthesis, impairs sleep architecture, and chronically elevates hs-CRP. Managing the cortisol axis is not a wellness indulgence — it is metabolic medicine.
Evidence-based compounds — from berberine to metformin, from NAD⁺ precursors to peptide protocols — can pharmacologically approximate the longevity signals produced by optimal lifestyle adherence. They are not substitutes for the first four pillars. They are amplifiers. Applied on top of a foundation of movement, sleep, nutrition, and stress management, they produce measurable, trackable biological age reversal.
Bryan Johnson's Blueprint programme — in which he spends approximately $2 million annually on his own biology — demonstrated a critical insight: continuous, granular measurement produces information that sporadic clinical testing cannot. His biological age, measured across multiple epigenetic clocks, has been independently verified as 5–10 years below his chronological age of 47 at most recent measurement. His protocol has generated the most longitudinal self-quantified biological dataset in existence.
The principle scales. You do not need $2M. You need the right 300 markers, measured at the right frequency, interpreted against the right reference ranges — calibrated for Indian biology, not European clinical trial populations.
| Marker | Standard range | Longevity optimal | Why it matters |
|---|---|---|---|
| ApoB | — | < 80 mg/dL | Particle count — the true driver of atherosclerosis. More predictive than LDL. Every 30mg/dL reduction = ~30% MACE reduction. |
| LDL-C | < 100 mg/dL | < 70 mg/dL | Cholesterol concentration — necessary but insufficient without ApoB. |
| Lp(a) | — | < 75 nmol/L | Genetically fixed. If elevated, changes the entire cardiovascular risk strategy permanently. |
| hs-CRP | < 5.0 mg/L | < 1.0 mg/L | Systemic inflammation — amplifies LDL-driven atherogenesis. The JUPITER trial showed hs-CRP elevation predicted MACE independently of LDL. |
| Triglycerides | < 150 mg/dL | < 100 mg/dL | VLDL overproduction signal — reflects carbohydrate and alcohol-driven hepatic lipogenesis. |
| ApoA1 | — | > 150 mg/dL | Functional HDL — reverse cholesterol transport capacity. More informative than HDL-C alone. |
| Marker | Standard range | Longevity optimal | Why it matters |
|---|---|---|---|
| HOMA-IR | < 2.0 | < 1.0 | Insulin resistance index. In South Asians, metabolic risk begins at HOMA-IR levels considered normal for Europeans. |
| Fasting insulin | 2–25 µU/mL | < 6 µU/mL | Hyperinsulinaemia precedes glucose dysregulation by 10–15 years — the first measurable metabolic signal. |
| HbA1c | < 5.7% | < 5.2% | 3-month integrated glucose — captures what fasting glucose misses. |
| Uric acid | < 7.0 mg/dL | < 5.5 mg/dL | Independent cardiovascular and metabolic risk marker. Elevated in HOMA-IR-driven states. |
| CGM — 14-day | — | Time in range > 90% | The most granular metabolic tool available. Reveals post-meal glucose spikes that fasting markers cannot. |
| Marker | Standard range | Longevity optimal | Why it matters |
|---|---|---|---|
| VO2 Max | Age-variable | Top 25th percentile for age | Single strongest predictor of all-cause mortality. Every 1 MET increase = ~13% mortality reduction. |
| HRV (7-day avg) | Age-variable | Trending upward | Autonomic nervous system recovery. Tracks real-time response to every intervention. |
| DunedinPACE | ~1.0 | < 0.85 | Rate of biological ageing. Responds to intervention within 12–24 weeks. |
| TruAge / GrimAge | Chronological age | 5+ years below chrono | Biological age — the integrated epigenetic readout of everything above. |
| IGF-1 | 100–300 ng/mL | 150–220 ng/mL | GH axis proxy — declines with age, linked to sarcopenia, cognitive decline, immune senescence. |
The most important pharmacological development of the last decade is not Ozempic for weight loss. It is what GLP-1 receptor agonists revealed about the multi-systemic nature of metabolic regulation — and what dual and triple agonists are beginning to demonstrate about the pharmacological addressability of ageing itself.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones secreted by the gut in response to feeding. Their receptors are expressed not just in the pancreas but across the brain, heart, kidney, liver, and vasculature — explaining why GLP-1 receptor agonists produce benefits that extend far beyond glycaemic control.
Generation 1: GLP-1 monotherapy. Semaglutide (Ozempic, Wegovy) — weekly subcutaneous injection, 14–17% weight loss in STEP trials, 20% MACE reduction in SELECT. India patent expired March 2026 — 50+ generics now available at a fraction of the original cost.
Generation 2: Dual incretin agonism. Tirzepatide (Mounjaro, Zepbound) — dual GLP-1/GIP agonist. Achieved 20.2% mean weight reduction at 72 weeks versus 13.7% for semaglutide in head-to-head SURMOUNT-5 trial. The dual mechanism targets complementary receptor populations, producing synergistic effects on visceral adipose tissue reduction specifically — the metabolic fat type that drives Indian cardiovascular and metabolic disease.
Generation 3: Triple agonism and precision dosing. Retatrutide (GLP-1/GIP/glucagon triple agonist) showed 24.2% weight loss at 48 weeks in Phase 2 — the highest weight loss ever observed in a pharmacological trial, approaching bariatric surgery outcomes. CagriSema (semaglutide + cagrilintide amylin analogue) showed 22–24% weight loss in early trials.
A landmark study published in Nature in 2025 — 27,885 participants, genome-wide association — identified a missense variant in GLP1R associated with significantly increased GLP-1 medication efficacy, producing an additional −0.76kg weight loss per copy of the effect allele. A separate GIPR locus was associated with nausea and vomiting specifically in tirzepatide-treated individuals.
This is the beginning of pharmacogenomic GLP-1 prescribing: your GLP1R genotype predicts which agonist will work best for you and at what dose. The same molecule is not the optimal choice for every patient. In 2027, genomically personalised incretin prescribing will be the clinical standard for programmes like 150.
"GLP-1 receptor agonists may be the first longevity drugs — not because they extend lifespan directly, but because they intervene simultaneously in cardiovascular disease, metabolic syndrome, MASH, kidney disease, and possibly neurodegeneration."
Nature Biotechnology, November 2025
Peptides are short amino acid chains — 2 to 100 residues — that function as biological signalling molecules. They are not hormones in the classical sense and not drugs in the pharmaceutical approval sense. They are endogenous regulatory compounds that the body makes in abundance at 20 and progressively less of with each passing decade.
The clinical use of therapeutic peptides represents the most targeted biological intervention currently available outside gene therapy. Unlike small molecule drugs that broadly inhibit or activate enzymatic pathways, peptides engage specific receptors with high selectivity — producing precise physiological effects with narrow off-target profiles.
Thymosin Alpha-1 (Zadaxin / Thymalfasin) — a 28-amino-acid peptide naturally produced by the thymus, approved in 35 countries including India for chronic hepatitis B, hepatitis C, and chemotherapy-related immune depression. Mechanism: toll-like receptor activation, NK cell and T-cell upregulation, dendritic cell maturation. Clinical application: post-DILI immune restoration, immune senescence in the context of ageing-associated thymic involution. Off-label longevity use: restore the immune competence that declines progressively after age 35 as thymic tissue involutes.
Semaglutide / Tirzepatide — as described in section 06. Prescription medications with the most robust human clinical trial evidence of any compound in the longevity pharmacopoeia.
CJC-1295 + Ipamorelin (GH secretagogue stack) — CJC-1295 is a synthetic analogue of GHRH (growth hormone-releasing hormone). Ipamorelin is a selective GHS-R (growth hormone secretagogue receptor) agonist. Used in combination, they stimulate pulsatile GH release — matching the body's natural nocturnal GH secretion pattern rather than flooding the system with exogenous GH. Clinical effects at 12 weeks: improved body composition (lean mass gain, visceral fat reduction), improved sleep architecture, elevated IGF-1 to youthful ranges. Published Phase 1 data in humans confirms the GH-stimulating profile. Long-term RCT data in healthy populations is limited.
BPC-157 (Body Protection Compound 157) — a 15-amino-acid stable gastric pentadecapeptide derived from a human gastric juice protein. Mechanism: VEGF-dependent angiogenesis, nitric oxide upregulation, gut-liver axis restoration, BPC-157 acts as a systemic stabilising peptide with documented anti-ulcer, gut-healing, and anti-inflammatory effects across 40+ peer-reviewed animal studies. Phase 2 human trials completed in Croatia (NCT02637284). Oral form is effective — BPC-157 survives gastric acid, making it uniquely suitable for oral administration among injectable peptides. FDA reclassified from Category 2 (restricted) to Category 1 (compoundable) in 2026.
MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) — a 16-amino-acid peptide encoded within the mitochondrial genome itself — not the nuclear genome. Discovered in 2015 by Lee et al. at USC. Mechanism: AMPK activation, insulin sensitisation in skeletal muscle, regulation of folate and methionine cycle — a completely novel metabolic regulatory pathway. Studies show MOTS-c declines with age and correlates with longevity in centenarian populations. Activates the same metabolic pathways as exercise and caloric restriction through a distinct molecular route.
GHK-Cu (Glycyl-L-histidyl-L-lysine copper peptide) — a tripeptide naturally produced in the liver that declines from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Mechanism: activates over 4,000 genes associated with DNA repair, antioxidant defence, anti-inflammatory signalling, and tissue remodelling. Strong hepatic anti-fibrotic evidence — specifically relevant to post-DILI liver recovery. Collagen synthesis stimulation is the most established clinical effect.
Epitalon (Epithalamin) — a tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology. Mechanism: telomerase activation (the first peptide demonstrated to elongate telomeres in human lymphocytes in published studies), pineal gland melatonin regulation, antioxidant. Russian clinical literature spanning 3 decades. Western peer review is limited but growing.
Semax — a synthetic analogue of ACTH (4-7) developed at the Institute of Molecular Genetics in Moscow. Mechanism: BDNF and NGF upregulation, neuroprotection, HPA axis modulation. Intranasal administration — crosses the blood-brain barrier directly. Used clinically in Russia and Ukraine for stroke rehabilitation and cognitive enhancement.
Supplements sit in a complex evidence landscape — stronger than placebo in many domains, weaker than pharmaceuticals in others, and profoundly dependent on form, dose, and standardisation. The 150 approach applies three filters: mechanistic plausibility from human biology, clinical evidence from randomised controlled trials or large observational studies, and safety profile appropriate for a recovering or healthy liver.
| Compound | Dose | Primary mechanism | Evidence anchor |
|---|---|---|---|
| Berberine HCl | 500mg 3× daily | AMPK activation, LDL receptor upregulation, gut microbiome modulation | Multiple RCTs showing 15–25 mg/dL LDL reduction and HOMA-IR improvement comparable to metformin (J Clin Endocrinol Metab, 2008) |
| Omega-3 EPA+DHA | 3g combined daily | TG reduction via PPAR-alpha, LDL oxidation prevention, anti-inflammatory via resolvins | REDUCE-IT trial: icosapentaenoic acid at 4g reduced MACE by 25% in high-risk patients. TG reduction 25–40% in RCTs across dose ranges. |
| Silymarin (Milk Thistle) | 140–420mg standardised | Hepatocyte membrane stabilisation, antioxidant, anti-fibrotic, UGT enzyme induction | Legalon (pharmaceutical silymarin) studied in 40+ RCTs for liver disease; hepatoprotective effect in DILI confirmed in systematic reviews |
| TUDCA | 500mg 2× daily | Bile acid pool modulation, mitochondrial membrane stabilisation, ER stress reduction | RCTs in NASH and cholestatic disease; first-line intravenous treatment for acute DILI in emergency medicine |
| NAC | 600mg 2× daily | Glutathione precursor (cysteine rate-limiting step), mucolytic, hepatoprotective | WHO Essential Medicine for paracetamol overdose (the gold standard DILI antidote); oral studies confirm glutathione elevation |
| Quercetin + Bromelain | 500mg daily | Senolytic (selective senescent cell clearance), NF-κB inhibition, hs-CRP reduction | Published senolytic activity in combination with dasatinib (Mayo Clinic); bromelain absorption enhancement confirmed |
| Magnesium Glycinate | 400mg daily | GABA-ergic sleep modulation, NMDA receptor regulation, insulin sensitivity | Meta-analysis: magnesium supplementation reduces fasting glucose and insulin in individuals with hypomagnesaemia (Diabetes Metab, 2017) |
| Vitamin D3 + K2 MK-7 | 5000 IU + 200mcg | VDR-mediated gene expression (LDL receptors, immune modulation, insulin secretion), calcium partitioning to bone | European Menopause guidelines; multiple RCTs on D3/K2 combination in calcium metabolism and cardiovascular risk |
| Compound | Dose | Primary mechanism | Evidence status |
|---|---|---|---|
| NMN (Nicotinamide Mononucleotide) | 750–1000mg daily | NAD⁺ precursor → sirtuin activation, mitochondrial biogenesis, DNA repair | Phase 1 and 2 RCTs confirm NAD⁺ elevation; lifespan extension in multiple animal models; human longevity effects under active investigation |
| Spermidine | 5mg daily | Autophagy induction (strongest food-derived autophagy inducer identified); polyamine pathway | Epidemiological data (Nat Med, 2018): higher dietary spermidine intake associated with lower all-cause mortality. RCTs in progress. |
| Astaxanthin | 12mg daily | Carotenoid antioxidant with unique mitochondrial membrane crossing; LDL oxidation inhibition; anti-inflammatory | Multiple small RCTs: hs-CRP reduction 20–30%, LDL oxidation markers improved, hepatoprotective in NASH models |
| CoQ10 Ubiquinol | 100mg daily | Mitochondrial electron transport chain cofactor, LDL oxidation prevention | Meta-analysis (2019): CoQ10 reduces TG and improves endothelial function; well-established mechanism in cardiac and mitochondrial medicine |
| Liposomal Glutathione | 250mg daily | Master cellular antioxidant, Phase 2 liver detoxification cofactor, immune function | Liposomal form specifically studied for bioavailability; synergistic with NAC |
| R-Alpha Lipoic Acid | 300mg daily | GLUT4 receptor upregulation (insulin sensitisation), antioxidant recycling (recycles vitamins C, E, CoQ10), hepatoprotective | Used clinically in Germany for diabetic neuropathy and DILI; multiple human studies confirming insulin sensitisation |
| Grape Seed OPC 95% | 300mg daily | LDL oxidation prevention, endothelial protection, NF-κB inhibition | Small RCTs confirming hs-CRP reduction and endothelial function improvement; 40-year safety history as food derivative |
The current standard of care prescribes the same statin dose to two patients with identical LDL levels — regardless of whether one carries the SLCO1B1*5 variant that increases statin-induced myopathy risk 17-fold. It prescribes the same GLP-1 agonist to two patients — regardless of whether one carries the GLP1R missense variant that predicts meaningfully different weight loss response.
Pharmacogenomics is the science of using genetic variants to predict drug efficacy, side effect risk, and optimal dosing. It is not a future technology. It is a present one with a limited but rapidly growing evidence base.
| Gene | Variant | Clinical relevance |
|---|---|---|
| ApoE (ε2/ε3/ε4) | rs429358, rs7412 | ApoE4 carriers have significantly elevated cardiovascular risk and require lower LDL targets. ApoE4 is also the strongest genetic risk factor for late-onset Alzheimer's. One test — permanent information. Changes lipid management strategy for life. |
| GLP1R | rs6923761 (Gly168Ser) | Associated with variable GLP-1 receptor agonist response — both glycaemic and weight outcomes. Published 2025 (Nature) — first large-scale GWAS of GLP-1 response in 27,885 individuals. |
| MTHFR | C677T, A1298C | Impairs conversion of dietary folate to active methylfolate. Associated with elevated homocysteine. Determines whether standard folate or methylfolate is required in B-vitamin supplementation. |
| SLCO1B1 | rs4149056 (*5 allele) | Impairs hepatic statin transporter. *5 carriers have 17× increased risk of statin-induced myopathy. Changes statin choice from simvastatin/atorvastatin to rosuvastatin or pravastatin. |
| VDR (Vitamin D receptor) | BsmI, ApaI, TaqI, FokI | Affects tissue response to vitamin D3 — two individuals with the same serum 25-OH-D can have very different functional vitamin D activity based on receptor polymorphisms. |
| CYP1A2 | rs762551 | Determines caffeine and certain drug metabolism rate. Relevant for cortisol management and certain peptide dosing protocols. |
By 2040, the standard entry point for an affluent Indian professional's healthcare relationship will not begin at the doctor's office when something breaks. It will begin at 35 with a full whole-genome sequence, a 300-marker biological age baseline, and a personalised longevity protocol adjusted quarterly based on continuous biomarker data.
The pharmacogenomic prescribing infrastructure will be mature. Your GLP1R genotype will determine your incretin choice. Your ApoE status will determine your LDL target. Your MTHFR status will be incorporated into your B-vitamin protocol from the first visit. Your SLCO1B1 status will be checked before the first statin is written.
AI models trained on longitudinal health datasets — biomarkers, protocols, outcomes, genomic markers — will provide prescribing intelligence that improves with every patient enrolled. The companies that own the training data will define the clinical standard. India's specific biological profile — the Asian Indian Phenotype, the dietary transition consequences, the genetically distinct ApoE and metabolic risk distributions — requires an Indian dataset. That dataset is being built today.
The 150 programme synthesises the longevity medicine frameworks of Sinclair, Attia, and Johnson — calibrated for Indian biology, operated under physician supervision, and tracked with monthly biomarker monitoring. It is not a wellness programme. It is a structured clinical intervention designed to measure and reverse biological ageing in a defined, trackable, and acquisition-ready way.
Objective: Hepatic recovery, metabolic correction, inflammatory load reduction. No Phase 2 compound is introduced until Phase 1 biomarker gates are met.
Compounds: TUDCA, NAC, Silymarin (liver recovery stack) · Berberine (metabolic correction, AMPK activation) · Omega-3 at therapeutic dose (TG reduction, anti-inflammatory) · Vitamin D3/K2 · Astaxanthin · CoQ10 Ubiquinol · Quercetin + Bromelain · Spermidine
Gate for Phase 2: ALT below 40 U/L for two consecutive monthly tests. IGF-1 baseline established. Hepatitis B vaccination series initiated.
Objective: GH axis restoration, immune competence, gut-liver axis repair, neuropeptide support.
Compounds: CJC-1295 + Ipamorelin (GH secretagogue, 300mcg SC nightly Mon–Fri) · Thymosin Alpha-1 / Zadaxin (immune axis, 1.5mg SC 2×/wk × 8 weeks) · BPC-157 oral (gut-liver axis, 500mcg daily) · Semax intranasal (cognitive, HPA modulation, working days)
Objective: Cellular rejuvenation, telomere support, mitochondrial optimisation, epigenetic age reversal measurement.
Compounds: MOTS-c (mitochondrial peptide, AMPK activation in skeletal muscle) · GHK-Cu (tissue regeneration, hepatic anti-fibrotic) · NMN 750–1000mg (NAD⁺ → sirtuin activation) · Epitalon (telomerase activation, 10-day course) · Thymosin Alpha-1 second cycle
Month 12: TruAge + DunedinPACE (biological age delta from baseline) · Galleri liquid biopsy · Full 300-marker panel · VO2 Max formal reassessment · DEXA body composition · CIMT
Every member is monitored monthly at minimum. The biomarker trajectory — not a single snapshot — is the clinical instrument. Monthly LFT tracks liver safety across all compound additions. Quarterly 300-marker panels track the full biological age reversal trajectory. Weekly HRV and fasting weight provide leading indicators between blood tests.
This monitoring architecture is not a safety measure bolted on to the protocol. It is the protocol. The data generated from every measurement, every protocol adjustment, and every 90-day outcome is the Indian Longitudinal Health Graph — the dataset that will define personalised longevity medicine for South Asian biology for decades.
"The goal is not to add years to life. It is to add life to years — and then, as a consequence of the biology being correct, the years follow."
Opening waitlist for Hyderabad — Q4 2027. Fifty members. Physician-managed. Built around your biology.
Apply at youlabs.co